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A B S T R A C T
Objectives: This study aimed to comprehensively compare the clinical features of hospitalized COVID-19
patients with hospitalized 2009 influenza pandemic patients.
Methods: Medline, Embase, Web of Science, Cochrane CENTRAL, and Google scholar were systematically
searched to identify studies related to COVID-19 and the 2009 influenza pandemic. The pooled incidence
rates of clinical features were estimated using the DerSimonian-Laird random-effects model with the
Freeman-Tukey double arcsine transformation method.
Results: The incidence rates of fever, cough, shortness of breath, sore throat, rhinorrhea, myalgia/muscle
pain, or vomiting were found to be significantly higher in influenza patients when compared with COVID-
19 patients. The incidence rates of comorbidities, including cardiovascular disease/hypertension and
diabetes, were significantly higher in COVID-19 compared with influenza patients. In contrast,
comorbidities such as asthma, chronic obstructive pulmonary disease, and immunocompromised
conditions were significantly more common in influenza compared with COVID-19 patients.
Unexpectedly, the estimated rates of intensive care unit admission, treatment with extracorporeal
membrane oxygenation, treatment with antibiotics, and fatality were comparable between hospitalized
COVID-19 and 2009 influenza pandemic patients.
Conclusions: This study comprehensively estimated the differences and similarities of the clinical features
and burdens of hospitalized COVID-19 and 2009 influenza pandemic patients. This information will be
important to better understand the current COVID-19 pandemic.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
The ongoing COVID-19 pandemic is spreading unprecedentedly,
and the eventual outcome of this pandemic remains largely
uncertain. The causative agent of COVID-19 – severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) – is highly
contagious (Rothan and Byrareddy, 2020). The clinical manifes-
tations of SARS-CoV-2 infection range from asymptomatic to
severe pneumonia, with some cases resulting in multiple organ
failure or death (Adhikari et al., 2020). The main reported
symptoms include fever, cough, shortness of breath, myalgia,
and fatigue (Huang et al., 2020). Death cases have primarily been
elderly people with comorbidities such as hypertension, coronary
heart disease and diabetes (Adhikari et al., 2020).
It has widely been recognized that SARS-CoV-2 and influenza
virus infections share substantial similarities in viral shedding,
transmission dynamics and clinical features of respiratory illnesses
(He et al., 2020; Petersen et al., 2020). Recent studies have
attempted to revisit the historical experience of 1918 and 2009
influenza pandemics, in order to learn lessons for better
understanding the current COVID-19 pandemic. These recent
studies have revealed similarities and differences in transmissibil-
ity, epidemic wave, and mortality rate between COVID-19 and
influenza pandemics (He et al., 2020; Petersen et al., 2020;
Petrosillo et al., 2020). It is believed that the published studies on
comparison between influenza and COVID-19 pandemics are
mainly focused on epidemiological features in the general
population (Petersen et al., 2020; Viboud and Simonsen, 2012).
In fact, the disease burden of both COVID-19 and influenza
pandemics largely lies in the hospitalized patient population,
which has not been systematically and comparatively studied.
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nd key clinical features of hospitalized patients between the 2009
nfluenza and COVID-19 pandemic.
ethods
ata sources and search strategies
A systematic search was conducted in Medline, Embase, Web of
cience, Cochrane CENTRAL, and Google scholar. Databases were
earched for articles in English language from inception until 2030.
ll searches from databases were performed by a biomedical
nformation specialist from the medical library. An exhaustive set
f search terms was used to identify studies providing clinical
eatures/outcomes of hospitalized patients for the 2009 H1N1
nfluenza or COVID-19 pandemic. The full search strategies are
rovided in the Supplementary file S1. This study was performed in
ccordance with the Preferred Reporting Items for Systematic
eviews and Meta-Analysis (PRISMA) guidelines.
election criteria
Studies were included if they met the following criteria: i) they
ontained clinical characteristics of SARS-CoV-2-confirmed
atients and ii) they contained clinical characteristics of 2009
andemic H1N1 influenza-confirmed patients. Studies were
xcluded if they met following criteria: i) they belonged to
ystematic review, meta-analysis, case reports, perspectives, or
onference abstracts; ii) they were animal coronavirus studies; iii)
hey had no primary data or incomplete data; iv) they had
uplicate data; and v) they were of low quality. Detailed full-text
eview and data extraction were independently performed by two
nvestigators: PL and YW. The investigators resolved discrepancies
y jointly reviewing the study in question. If no consensus was
eached, another reviewer (QP) functioned as an arbiter to resolve
isagreements.
ata extraction and quality assessment
Eligible studies were further screened to extract data. In cases of
ultiple studies involving the same population, the most
omprehensive or most recent one was included. The quality of
tudies was assessed using the Joanna Briggs Institute checklist for
revalence/incidence studies, which enabled assessment of
ncluded studies in relation to risk of bias, rigour, and transparency
Munn et al., 2020). Studies scoring 1–3 were defined as low-
uality, 4–6 as average-quality, and 7–9 as high-quality (Supple-
entary data Table 1).
Statistics analysis
After checking for consistency, the Metaprop module in the R-
3.6.3 statistical software package (Version 3.6.3 for Windows,
Foundation for Statistical Computing, Vienna, Austria) was used for
meta-analysis. A 95% confidence interval (95% CI) was estimated
using the Wilson score method, and the pooled incidence rate was
calculated by the DerSimonian-Laird random-effects model with
the Freeman-Tukey double arcsine transformation method.
Statistical heterogeneity was assessed using the Cochran Q
statistics and I2 statistics, with I2 statistics categorized as low (I2
= 25–50%), moderate (I2 = 50–75%), high (I2 >75%), or no statistical
heterogeneity (I2 = 0%). A random-effects model was used when
the heterogeneity was >50%. The Mann-Whitney test (nonpara-
metric test) was used to compare the COVID-19 and 2009 influenza
pandemic patient groups. A p-value < 0.05 was considered as
significant.
Results
Study and patient characteristics
The database search yielded 21,986 records after excluding
replications. A total of 113 studies with 36,422 hospitalized COVID-
19 patients and 84 studies with 23,167 hospitalized influenza
patients were finally included (Figure 1). Patients from the two
pandemics had similar sex distributions, with slightly >50% being
male. The average age of hospitalized COVID-19 patients was 52
years (SD  16.93), which was much older than the influenza
patients (average 26 years, SD  15.57) (Table 1).
Comparative analysis of symptoms and comorbidities between
hospitalized COVID-19 and influenza patients
The highest prevalent symptom in hospitalized COVID-19
patients was fever (72.08%, 95% CI 63.27–80.13; I2 = 99%), followed
by cough (57.99%, 95% CI 53.32–62.59; I2 = 97%), shortness of breath
(32.89%, 95% CI 27.09–38.95; I2 = 98%), fatigue (30.20%, 95% CI
24.75–35.93; I2 = 96%), myalgia/muscle pain (18.97%, 95% CI 14.23–
24.20; I2 = 98%), diarrhea (10.16%, 95% CI 7.23–13.51; I2 = 97%), sore
throat (9.48%, 95% CI 7.47–11.69; I2 = 88%), vomiting/nausea (8.67%,
95% CI 5.40–12.59; I2 = 98%), and rhinorrhea (8.48%, 95% CI 6.02–
11.28; I2 = 92%) (Figure 2, Supplementary S2–10). Fever and cough
were the most common symptoms in hospitalized 2009 influenza
patients, with incidence rates of 89.99% (95% CI 87.64–92.13; I2 = 9
6%) and 85.31% (95% CI 82.84–87.63; I2 = 95%), respectively,
followed by shortness of breath (49.19%, 95% CI 40.40–58.01; I2 =
98%), fatigue (48.20%, 95% CI 29.64–67.03; I2 = 99%), rhinorrhea
able 1
haracteristics, management and outcome of hospitalized COVID-19 and 2009 influenza patients.
COVID-19 pandemic 2009 influenza pandemic
Characteristics Estimates
(95% CI)
Study No. Patient No. Estimates
(95% CI)
Study No. Patient No. p-value
Sex (male%) 20,425 (56.08%) 113 36,422 12,556 (54.20%) 84 23,167 /
Age, years (mean  SD, range) 52.11  16.93 (0.2–96) 37 5085 26.27  15.57 (0–94) 47 12,347 /
Management
Antibiotics use 67.44% (51.91–81.27) 23 5350 60.45% (47.93–72.31) 13 2569 0.3081
Mechanical ventilation 27.10% (20.91–33.75) 46 17,101 14.70% (6.65–25.12) 13 4975 0.0603
ECMO 3.10% (1.45–5.25) 19 6644 5.79% 2 863 /
ICU admission 17.74% (13.93–21.89) 35 15,636 16.03% (11.55–21.06) 36 9083 0.4416
Outcome
Death 12.94% (10.93–15.10) 54 25,390 9.63% (6.05–13.90) 28 5075 0.1682
bbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
376
Figure 1. Study selection.
Figure 2. Forest plot of incidence rate of common symptoms in hospitalized COVID-19 and 2009 influenza pandemic patients.
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2.00–42.70; I2 = 98%), myalgia/muscle pain (30.12%, 95% CI 24.68–
5.84; I2 = 98%), vomiting/nausea (24.27%, 95% CI 20.51–28.25; I2 =
6%), and diarrhea (11.27%, 95% CI 9.63–13.01; I2 = 91%) (Figure 2;
upplementary S11–19). Notably, cough (85.31% vs. 57.99%), fever
89.99% vs. 72.08%), shortness of breath (49.19% vs. 32.89%), sore
hroat (37.28% vs. 9.48%), rhinorrhea (38.57% vs. 8.48%), myalgia/
uscle pain (30.12% vs. 18.97%), and vomiting (24.27% vs. 8.67%)
ere significantly higher in influenza than COVID-19 patients (p <
.05; Table 2). It was estimated that 27.60% (95% CI 17.55–38.93; I2
 98%) of H1N1 patients presented with pneumonia symptoms
Supplementary S20). However, the included COVID-19 studies
rovided little information on the rate of pneumonia. A recent
tudy reported that 86.1% of hospitalized COVID-19 patients were
diagnosed with ground-glass opacities in the lungs (Zhao et al.,
2020), which is highly related to pneumonia symptoms.
Cardiovascular disease/hypertension was the most common
comorbidity in hospitalized COVID-19 patients (28.76%, 95% CI
22.91–34.99; I2 = 99%), followed by obesity (28.48%, 95% CI 19.04–
38.94; I2 = 99%), diabetes (16.38%, 95% CI 13.65–19.30; I2 = 98%),
heart disease (12.89%, 95% CI 9.71–16.43; I2 = 97%), asthma (8.42%,
95% CI 6.69–10.32; I2 = 80%), and renal disease (8.10%, 95% CI 5.93–
10.56; I2 = 97%) (Figure 3; Supplementary data S21–29). Obesity
was the most common comorbidity in influenza patients, with
incidence rates of 17.89% (95% CI 13.40–22.86; I2 = 98%), followed
by asthma (16.09%, 95% CI 13.15–19.26; I2 = 96%), cardiovascular
disease/hypertension (13.11%, 95% CI 10.84–15.55; I2 = 91%),
diabetes (11.12%, 95% CI 9.39–12.97; I2 = 92%),
able 2
omparative analysis of symptoms and comorbidities in hospitalized COVID-19 and 2009 influenza patients.
COVID-19 pandemic 2009 influenza pandemic
Characteristics Estimates(95% CI) Study No. Patient No. Estimates
(95% CI)
Study No. Patient No. p-value
Symptoms
Cough 57.99% (53.32–62.59) 56 14,717 85.31% (82.84–87.63) 82 20,710 < 0.0001
Fever 72.08% (63.27–80.13) 57 16,006 89.99% (87.64–92.13) 78 20,571 < 0.0001
Diarrhea 10.16% (7.23–13.51) 41 14,434 11.27% (9.63–13.01) 63 17,433 0.3897
Fatigue 30.20% (24.75–35.93) 34 6,875 48.20% (29.64–67.03) 16 4391 0.0965
Shortness of breath 32.89% (27.09–38.95) 54 14,211 49.19% (40.40–58.01) 25 5521 0.0249
Sore throat 9.48% (7.47–11.69) 34 8502 37.28% (32.00–42.70) 61 17,268 < 0.0001
Rhinorrhea 8.48% (6.02–11.28) 27 8040 38.57% (33.11–44.17) 55 15,997 < 0.0001
Myalgia/muscle pain 18.97% (14.23–24.20) 36 12,865 30.12% (24.68–35.84) 68 16,940 0.0242
Vomiting/nausea 8.67% (5.40–12.59) 27 13,174 24.27% (20.51–28.25) 52 12,846 < 0.0001
Comorbidity
Cardiovascular disease/ Hypertension 28.76% (22.91–34.99) 83 33,019 13.11% (10.84–15.55) 41 10,144 < 0.0001
Obesity 28.48% (19.04–38.94) 18 12,819 17.89% (13.40–22.86) 46 13,409 0.1081
Diabetes 16.38% (13.65–19.30) 89 33,407 11.12% (9.39–12.97%) 58 17,031 0.0120
Asthma 8.42% (6.69–10.32) 19 7732 16.09% (13.15–19.26) 53 16,034 0.0033
COPD 4.93% (3.78–6.21) 44 14,107 9.52% (7.09–12.24) 37 11,493 0.0003
Immunocompromised 4.39% (2.50–6.71) 29 9111 9.99% (8.30–11.82) 48 17,521 < 0.0001
Cancer/malignancy 4.75% (3.59–6.06) 40 23,815 5.76% (4.09–7.67) 25 6557 0.2906
Heart disease 12.89% (9.71–16.43) 43 13,876 8.66% (6.30–11.34) 28 7396 0.2249
Renal disease 8.10% (5.93–10.56) 56 26,016 4.90% (3.86–6.05) 35 9793 0.1676
OPD, chronic obstructive pulmonary disease.Figure 3. Forest plot of incidence rate of comorbidities in hospitalized COVID-19 and 2009 influenza patients.
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92%), chronic obstructive pulmonary disease (COPD) (9.52%, 95% CI
7.09–12.24; I2 = 94%), heart disease (8.66%, 95% CI 6.30–11.34; I2 =
92%), cancer/malignancy (5.76%, 95% CI 4.09–7.67; I2 = 88%) and
renal disease (4.90%, 95% CI 3.86–6.05%; I2 = 79%) (Figure 3;
Supplementary data S30–38). Importantly, the estimated inci-
dence rates of cardiovascular disease/hypertension (28.76% vs.
13.11%) and diabetes (16.38% vs.11.12%) were significantly higher in
COVID-19 compared with influenza patients. In contrast, comor-
bidities such as asthma (16.09% vs. 8.42%), COPD (9.52% vs. 4.93%)
and immunocompromised conditions (9.99% vs. 4.39%) were
significantly more common in influenza patients compared with
COVID-19 patients (p < 0.05; Table 2).
Comparative analysis of clinical management and outcome between
hospitalized COVID-19 and influenza patients
Clinical management for hospitalized COVID-19 and influenza
patients was comparatively analyzed. Because secondary bacterial
infections are common after viral infection, antibiotics were
widely used in these patients. It was found that the frequency of
antibiotic treatment was similar between hospitalized COVID-19
(67.44%, 95% CI 51.91–81.27; I2 = 99%) and H1N1 (60.45%, 95% CI
47.93–72.31; I2 = 97%) patients (Table 1). Unexpectedly, the
estimated rates of intensive care unit (ICU) admissions (17.74%, 95%
CI 13.93–21.89 vs. 16.03%, 95% CI 11.52–21.06) and treatment with
extracorporeal membrane oxygenation (ECMO) (3.10%, 95% CI
1.45–5.25 vs. 5.79%) were comparable between hospitalized
COVID-19 and 2009 influenza pandemic patients. Treatment with
mechanical ventilation appeared to be more common in COVID-19
(27.10%, 95% CI 20.91–33.75; I2 = 99%) than influenza (14.70%, 95%
CI 6.65%–25.12%; I2 = 99%) patients, although this was not
statistically significant. Most surprisingly, the fatality rate of
hospitalized patients was slightly higher in COVID-19 (12.94%, 95%
CI 10.93–15.10; I2 = 95%) than 2009 influenza patients (9.63%, 95%
CI 6.05–13.90; I2 = 95%) (Table 1; Supplementary data 39–47).
Discussion
This study provided a comprehensive comparison of hospital-
ized patients between the 2009 influenza and COVID-19 pan-
demics, regarding demographics, symptoms, comorbidity,
management, and outcomes. Hospitalized COVID-19 patients
compared with influenza patients were much older. This supports
the notion that SARS-CoV-2 primarily causes severe diseases in the
elderly (Verity et al., 2020), whereas H1N1 influenza severely
affected younger populations (Reed et al., 2014; Viboud and
Simonsen, 2012). Besides the common symptoms of respiratory
infections, it was found that a proportion of patients from both
pandemics had diarrhea and vomiting/nausea symptoms. Both
SARS-CoV-2 and influenza viruses have been shown to effectively
infect and replicate in the intestinal epithelium (Qu et al., 2012;
Xiao et al., 2020), causing gastrointestinal symptoms in patients
(Gu et al., 2020; Patel et al., 2010). Consistent with previous studies
reporting cardiovascular disease, hypertension and diabetes as risk
factors of COVID-19 (Zhou et al., 2020), a substantially high
incidence rate of these comorbidities was found in COVID-19
patients.
It was clear that the severity and mortality of SARS-CoV-2
infection were much higher than those of the influenza infection in
hospitalized patients. Hospitalized COVID-19 and 2009 influenza
patients consistently had similar death rates (12.94% vs. 9.63%).
This study focused on comparing COVID-19 patients with 2009
pandemic influenza H1N1 patients; however, it would also be
interesting to compare with seasonal flu caused by influenza A and
B viruses. Hospitalized pandemic H1N1 patients in this analysis
appeared to have higher frequencies of fever, fatigue, vomiting,
shortness of breath, and diarrhea compared with hospitalized
seasonal influenza patients (Zhang et al., 2020). However,
comorbidities – including diabetes, COPD, immunocompromised
status, and heart disease – seemed more common in seasonal
influenza patients compared with H1N1 pandemic patients
(Mohammad et al., 2019). Nevertheless, future studies are required
to comprehensively, for example by systematic review and meta-
analysis, compare COVID-19 with pandemic and seasonal influen-
za.
There has been recent attention on comparing COVID-19 with
influenza or the infection of classical endemic coronaviruses in
pediatric populations. A comparison between children with
COVID-19 and seasonal influenza showed no differences in
hospitalization rates, ICU admission rates, and mechanical
ventilator use (Song et al., 2020). In infants aged <1 year, major
differences in the clinical features are unlikely when comparing
SARS-CoV-2 with classical endemic coronaviruses or influenza
virus symptoms (Li et al., 2020a, 2020b; Vanhems et al., 2020).
Interestingly, some studies suggest that clinical manifestations of
COVID-19 are even milder than influenza A in children aged <5
years (Li et al., 2020c).
This study had some limitations. First, the criteria for
hospitalization may have differed across different studies, result-
ing in patient selection bias. Second, it was unable to estimate the
incidence rate of ECMO treatment for 2009 influenza patients
because only two studies were available. Third, the number of
available studies on the 2009 influenza pandemic was limited,
which may have caused estimation bias. Finally, the COVID-19
pandemic is still ongoing and evolving. Future studies may update
the current estimations on the clinical features of hospitalized
COVID-19 patients.
In summary, this meta-analysis comprehensively deciphered
the clinical features for hospitalized patients comparing COVID-19
with the 2009 influenza pandemic. Similar levels of disease burden
were found in hospitalized COVID-19 and influenza patients from
these two pandemics. This is in contrast with the assumption for
the general population that COVID-19 causes much more severe
damage compared to influenza. Thus, the devastating situation of
COVID-19 could be mainly attributed to the rapid spread and it
affecting a large population, whereas the spread of the 2009
pandemic influenza was relatively limited and affected a smaller
population.
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